{"id": "HPRD50.d1.s3_HPRD50.d1.s3.p0", "text": "To identify the regions of MCP-1 that contact its receptor, CCR2, we substituted all surface-exposed residues with alanine", "text_with_entity_marker": "To identify the regions of [E1]MCP-1[/E1] that contact its receptor, [E2]CCR2[/E2], we substituted all surface-exposed residues with alanine", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "MCP-1", "entity_1_idx": [[27, 32]], "entity_1_idx_in_text_with_entity_marker": [31, 36], "entity_1_type": "pm0111607||pm0117207||pm0124628", "entity_1_type_id": 5, "entity_2": "CCR2", "entity_2_idx": [[60, 64]], "entity_2_idx_in_text_with_entity_marker": [73, 77], "entity_2_type": "pm0111607", "entity_2_type_id": 4}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s0_HPRD50.d2.s0.p1", "text": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer", "text_with_entity_marker": "We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the [E1]CG beta[/E1] subunit or the CG beta alpha and [E2]FSH beta[/E2] monomer", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[94, 101]], "entity_1_idx_in_text_with_entity_marker": [98, 105], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[135, 143]], "entity_2_idx_in_text_with_entity_marker": [148, 156], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s2_HPRD50.d5.s2.p0", "text": "Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of LFA-1 depends on its interaction with cytohesin-1, unless the integrin is activated by exogenous divalent cations", "text_with_entity_marker": "Mutational analyses of the beta-2 cytoplasmic domain revealed that the adhesive function of [E1]LFA-1[/E1] depends on its interaction with [E2]cytohesin-1[/E2], unless the integrin is activated by exogenous divalent cations", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LFA-1", "entity_1_idx": [[92, 97]], "entity_1_idx_in_text_with_entity_marker": [96, 101], "entity_1_type": "pm0104657||pm0114514", "entity_1_type_id": 21, "entity_2": "cytohesin-1", "entity_2_idx": [[130, 141]], "entity_2_idx_in_text_with_entity_marker": [143, 154], "entity_2_type": "pm0124251", "entity_2_type_id": 20}], "directed": false, "reverse": false}
{"id": "HPRD50.d5.s3_HPRD50.d5.s3.p0", "text": "Secondly, cytohesin-1 induces expression of an extracellular activation epitope of LFA-1, and the exchange factor function is not essential for this activity", "text_with_entity_marker": "Secondly, [E1]cytohesin-1[/E1] induces expression of an extracellular activation epitope of [E2]LFA-1[/E2], and the exchange factor function is not essential for this activity", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "cytohesin-1", "entity_1_idx": [[10, 21]], "entity_1_idx_in_text_with_entity_marker": [14, 25], "entity_1_type": "pm0124251", "entity_1_type_id": 20, "entity_2": "LFA-1", "entity_2_idx": [[83, 88]], "entity_2_idx_in_text_with_entity_marker": [96, 101], "entity_2_type": "pm0104657||pm0114514", "entity_2_type_id": 21}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s1_HPRD50.d6.s1.p0", "text": "These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of Jak2, p125FAK, and paxillin and actin polymerization", "text_with_entity_marker": "These results suggest that pituitary GH modulates neutrophil adhesion through tyrosine phosphorylation of [E1]Jak2[/E1], p125FAK, and [E2]paxillin[/E2] and actin polymerization", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Jak2", "entity_1_idx": [[106, 110]], "entity_1_idx_in_text_with_entity_marker": [110, 114], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "paxillin", "entity_2_idx": [[125, 133]], "entity_2_idx_in_text_with_entity_marker": [138, 146], "entity_2_type": "pm0119378", "entity_2_type_id": 24}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p0", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the [E1]NF-E2[/E1]/[E2]AP-1[/E2] site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NF-E2", "entity_1_idx": [[50, 55]], "entity_1_idx_in_text_with_entity_marker": [54, 59], "entity_1_type": "pm0120477", "entity_1_type_id": 28, "entity_2": "AP-1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0103880", "entity_2_type_id": 29}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s2_HPRD50.d7.s2.p5", "text": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor NRF2 (NF-E2-related factor 2)", "text_with_entity_marker": "By electrophoretic mobility shift assay using the NF-E2/AP-1 site and nuclear extracts from macrophages, we observed a specific protein-DNA complex formation, which was inhibited by a specific antibody against the transcription factor [E1]NRF2[/E1] ([E2]NF-E2-related factor 2[/E2])", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NRF2", "entity_1_idx": [[235, 239]], "entity_1_idx_in_text_with_entity_marker": [239, 243], "entity_1_type": "pm0105918||pm0123857", "entity_1_type_id": 27, "entity_2": "NF-E2-related factor 2", "entity_2_idx": [[241, 263]], "entity_2_idx_in_text_with_entity_marker": [254, 276], "entity_2_type": "pm0105918", "entity_2_type_id": 30}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p2", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify CD43 as a T cell counterreceptor for [E1]sialoadhesin[/E1] and suggest that in addition to its anti-adhesive role [E2]CD43[/E2] may promote cell-cell interactions", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "sialoadhesin", "entity_1_idx": [[60, 72]], "entity_1_idx_in_text_with_entity_marker": [64, 76], "entity_1_type": "pm0108007", "entity_1_type_id": 37, "entity_2": "CD43", "entity_2_idx": [[128, 132]], "entity_2_idx_in_text_with_entity_marker": [141, 145], "entity_2_type": "pm0122945", "entity_2_type_id": 36}], "directed": false, "reverse": false}
{"id": "HPRD50.d11.s1_HPRD50.d11.s1.p0", "text": "This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85alpha, activates PI 3-kinase by mediating its recruitment to the membrane", "text_with_entity_marker": "This suggests that transmembrane [E1]ADAM 12[/E1], by providing docking sites for the Src homology 3 domain of [E2]p85alpha[/E2], activates PI 3-kinase by mediating its recruitment to the membrane", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "ADAM 12", "entity_1_idx": [[33, 40]], "entity_1_idx_in_text_with_entity_marker": [37, 44], "entity_1_type": "pm0118647", "entity_1_type_id": 39, "entity_2": "p85alpha", "entity_2_idx": [[102, 110]], "entity_2_idx_in_text_with_entity_marker": [115, 123], "entity_2_type": "pm0124741", "entity_2_type_id": 40}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p1", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that [E2]CLIP-170[/E2] and LIS1 regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "CLIP-170", "entity_2_idx": [[158, 166]], "entity_2_idx_in_text_with_entity_marker": [171, 179], "entity_2_type": "pm0124985", "entity_2_type_id": 43}], "directed": false, "reverse": false}
{"id": "HPRD50.d13.s1_HPRD50.d13.s1.p2", "text": "Overexpression of CLIP-170 results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and LIS1 regulate dynein/dynactin binding to MTs", "text_with_entity_marker": "Overexpression of [E1]CLIP-170[/E1] results in a zinc finger-dependent localization of a phospho-LIS1 isoform and dynactin to MT bundles, raising the possibility that CLIP-170 and [E2]LIS1[/E2] regulate dynein/dynactin binding to MTs", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CLIP-170", "entity_1_idx": [[18, 26]], "entity_1_idx_in_text_with_entity_marker": [22, 30], "entity_1_type": "pm0124985", "entity_1_type_id": 43, "entity_2": "LIS1", "entity_2_idx": [[171, 175]], "entity_2_idx_in_text_with_entity_marker": [184, 188], "entity_2_type": "pm0110467", "entity_2_type_id": 44}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s0_HPRD50.d16.s0.p2", "text": "GADD45b and GADD45g are cdc2/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "text_with_entity_marker": "GADD45b and [E1]GADD45g[/E1] are [E2]cdc2[/E2]/cyclinB1 kinase inhibitors with a role in S and G2/M cell cycle checkpoints induced by genotoxic stress", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GADD45g", "entity_1_idx": [[12, 19]], "entity_1_idx_in_text_with_entity_marker": [16, 23], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "cdc2", "entity_2_idx": [[24, 28]], "entity_2_idx_in_text_with_entity_marker": [37, 41], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p1", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether [E1]Gadd45b[/E1] and/or Gadd45g function as inhibitors of [E2]cdc2[/E2]/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45b", "entity_1_idx": [[13, 20]], "entity_1_idx_in_text_with_entity_marker": [17, 24], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "cdc2", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p5", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and [E1]Gadd45g[/E1], as well as GADD45a, interact with both [E2]Cdk1[/E2] and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "Cdk1", "entity_2_idx": [[93, 97]], "entity_2_idx_in_text_with_entity_marker": [106, 110], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p3", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by [E1]Gadd45b[/E1] and [E2]Gadd45a[/E2] was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45a", "entity_2_idx": [[59, 66]], "entity_2_idx_in_text_with_entity_marker": [72, 79], "entity_2_type": "pm0112301", "entity_2_type_id": 54}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s0_HPRD50.d18.s0.p0", "text": "The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)", "text_with_entity_marker": "The transmembrane [E1]receptor protein tyrosine phosphatase[/E1] [E2]DEP1[/E2] interacts with p120(ctn)", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor protein tyrosine phosphatase", "entity_1_idx": [[18, 55]], "entity_1_idx_in_text_with_entity_marker": [22, 59], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "DEP1", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d18.s1_HPRD50.d18.s1.p0", "text": "The receptor-like protein tyrosine phosphatase DEP1, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "text_with_entity_marker": "The [E1]receptor-like protein tyrosine phosphatase[/E1] [E2]DEP1[/E2], also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "receptor-like protein tyrosine phosphatase", "entity_1_idx": [[4, 46]], "entity_1_idx_in_text_with_entity_marker": [8, 50], "entity_1_type": "pm0104157", "entity_1_type_id": 58, "entity_2": "DEP1", "entity_2_idx": [[47, 51]], "entity_2_idx_in_text_with_entity_marker": [60, 64], "entity_2_type": "pm0115917", "entity_2_type_id": 59}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s1_HPRD50.d19.s1.p2", "text": "p300/cAMP-response-element-binding-protein ('CREB')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "text_with_entity_marker": "p300/[E1]cAMP-response-element-binding-protein[/E1] ('[E2]CREB[/E2]')-binding protein (CBP) interacting with transcription factors is able to increase their activity on target gene promoters", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cAMP-response-element-binding-protein", "entity_1_idx": [[5, 42]], "entity_1_idx_in_text_with_entity_marker": [9, 46], "entity_1_type": "pm0100874", "entity_1_type_id": 66, "entity_2": "CREB", "entity_2_idx": [[45, 49]], "entity_2_idx_in_text_with_entity_marker": [58, 62], "entity_2_type": "pm0100874", "entity_2_type_id": 66}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p1", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "[E1]GC-GAP[/E1], a Rho family GTPase-activating protein that interacts with signaling adapters [E2]Gab1[/E2] and Gab2", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "GC-GAP", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0122639", "entity_1_type_id": 73, "entity_2": "Gab1", "entity_2_idx": [[86, 90]], "entity_2_idx_in_text_with_entity_marker": [99, 103], "entity_2_type": "pm0112697", "entity_2_type_id": 75}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s0_HPRD50.d22.s0.p5", "text": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters Gab1 and Gab2", "text_with_entity_marker": "GC-GAP, a Rho family GTPase-activating protein that interacts with signaling adapters [E1]Gab1[/E1] and [E2]Gab2[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gab1", "entity_1_idx": [[86, 90]], "entity_1_idx_in_text_with_entity_marker": [90, 94], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Gab2", "entity_2_idx": [[95, 99]], "entity_2_idx_in_text_with_entity_marker": [108, 112], "entity_2_type": "pm0111574", "entity_2_type_id": 76}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s3_HPRD50.d22.s3.p2", "text": "We propose that Gab1 and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and Cdc42 activities", "text_with_entity_marker": "We propose that [E1]Gab1[/E1] and Gab2 in cooperation with other adapter molecules might regulate the cellular localization of GC-GAP under specific stimuli, acting to regulate precisely Rac and [E2]Cdc42[/E2] activities", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab1", "entity_1_idx": [[16, 20]], "entity_1_idx_in_text_with_entity_marker": [20, 24], "entity_1_type": "pm0112697", "entity_1_type_id": 75, "entity_2": "Cdc42", "entity_2_idx": [[186, 191]], "entity_2_idx_in_text_with_entity_marker": [199, 204], "entity_2_type": "pm0110789", "entity_2_type_id": 80}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s0_HPRD50.d23.s0.p0", "text": "A role for Plk1 phosphorylation of NudC in cytokinesis", "text_with_entity_marker": "A role for [E1]Plk1[/E1] phosphorylation of [E2]NudC[/E2] in cytokinesis", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Plk1", "entity_1_idx": [[11, 15]], "entity_1_idx_in_text_with_entity_marker": [15, 19], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "NudC", "entity_2_idx": [[35, 39]], "entity_2_idx_in_text_with_entity_marker": [48, 52], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p11", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that [E1]Plk1[/E1] phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[71, 75]], "entity_1_idx_in_text_with_entity_marker": [75, 79], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p4", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the LDL receptor ([E1]LDLR[/E1]) promoter mediates oncostatin M (OM)-induced transcription of the [E2]LDLR[/E2] gene through a cholesterol-independent pathway", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "LDLR", "entity_1_idx": [[70, 74]], "entity_1_idx_in_text_with_entity_marker": [74, 78], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "LDLR", "entity_2_idx": [[141, 145]], "entity_2_idx_in_text_with_entity_marker": [154, 158], "entity_2_type": "pm0125757", "entity_2_type_id": 88}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s2_HPRD50.d25.s2.p0", "text": "The interaction between AR and TR2 was assessed by glutathione-S-transferase (GST) pull-down assay and mammalian two-hybrid system assay", "text_with_entity_marker": "The interaction between AR and [E1]TR2[/E1] was assessed by [E2]glutathione-S-transferase[/E2] (GST) pull-down assay and mammalian two-hybrid system assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TR2", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "glutathione-S-transferase", "entity_2_idx": [[51, 76]], "entity_2_idx_in_text_with_entity_marker": [64, 89], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s2_HPRD50.d26.s2.p3", "text": "TBP-1 associates with the beta-domain of pVHL and complexes with pVHL and Hif1 alpha in vivo", "text_with_entity_marker": "TBP-1 associates with the beta-domain of [E1]pVHL[/E1] and complexes with [E2]pVHL[/E2] and Hif1 alpha in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[41, 45]], "entity_1_idx_in_text_with_entity_marker": [45, 49], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "pVHL", "entity_2_idx": [[65, 69]], "entity_2_idx_in_text_with_entity_marker": [78, 82], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p6", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade [E1]Hif1 alpha[/E1] depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Hif1 alpha", "entity_1_idx": [[37, 47]], "entity_1_idx_in_text_with_entity_marker": [41, 51], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p7", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with [E1]TBP-1[/E1] and suggests a new mechanism for [E2]Hif1 alpha[/E2] stabilization in some pVHL-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TBP-1", "entity_1_idx": [[88, 93]], "entity_1_idx_in_text_with_entity_marker": [92, 97], "entity_1_type": "pm0113245||pm0120764", "entity_1_type_id": 95, "entity_2": "Hif1 alpha", "entity_2_idx": [[127, 137]], "entity_2_idx_in_text_with_entity_marker": [140, 150], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s0_HPRD50.d29.s0.p0", "text": "Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription", "text_with_entity_marker": "Modification of de novo DNA methyltransferase 3a ([E1]Dnmt3a[/E1]) by [E2]SUMO-1[/E2] modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[50, 56]], "entity_1_idx_in_text_with_entity_marker": [54, 60], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[61, 67]], "entity_2_idx_in_text_with_entity_marker": [74, 80], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p5", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme [E1]Ubc9[/E1] and the E3 sumo ligases PIAS1 and [E2]PIASxalpha[/E2], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Ubc9", "entity_1_idx": [[128, 132]], "entity_1_idx_in_text_with_entity_marker": [132, 136], "entity_1_type": "pm0110323", "entity_1_type_id": 105, "entity_2": "PIASxalpha", "entity_2_idx": [[167, 177]], "entity_2_idx_in_text_with_entity_marker": [180, 190], "entity_2_type": "pm0119764", "entity_2_type_id": 107}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s2_HPRD50.d29.s2.p0", "text": "Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "text_with_entity_marker": "[E1]Dnmt3a[/E1] is modified by [E2]SUMO-1[/E2] in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "SUMO-1", "entity_2_idx": [[22, 28]], "entity_2_idx_in_text_with_entity_marker": [35, 41], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s3_HPRD50.d29.s3.p0", "text": "Functionally, sumoylation of Dnmt3a disrupts its ability to interact with histone deacetylases (HDAC1/2), but not with another interaction partner, Dnmt3b", "text_with_entity_marker": "Functionally, sumoylation of [E1]Dnmt3a[/E1] disrupts its ability to interact with histone deacetylases ([E2]HDAC1[/E2]/2), but not with another interaction partner, Dnmt3b", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Dnmt3a", "entity_1_idx": [[29, 35]], "entity_1_idx_in_text_with_entity_marker": [33, 39], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "HDAC1", "entity_2_idx": [[96, 101]], "entity_2_idx_in_text_with_entity_marker": [109, 114], "entity_2_type": "pm0119729", "entity_2_type_id": 108}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s0_HPRD50.d32.s0.p5", "text": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease", "text_with_entity_marker": "Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, [E1]decorin[/E1], and [E2]versican[/E2]) to the beta-amyloid protein of Alzheimer's disease", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[81, 88]], "entity_1_idx_in_text_with_entity_marker": [85, 92], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "versican", "entity_2_idx": [[94, 102]], "entity_2_idx_in_text_with_entity_marker": [107, 115], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p2", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of [E1]perlecan[/E1], a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "perlecan", "entity_1_idx": [[61, 69]], "entity_1_idx_in_text_with_entity_marker": [65, 73], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p6", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC [E1]PGs[/E1] bound to A beta (1-28) revealed strong binding by [E2]perlecan[/E2], weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PGs", "entity_1_idx": [[31, 34]], "entity_1_idx_in_text_with_entity_marker": [35, 38], "entity_1_type": "pm0108066", "entity_1_type_id": 121, "entity_2": "perlecan", "entity_2_idx": [[85, 93]], "entity_2_idx_in_text_with_entity_marker": [98, 106], "entity_2_type": "pm0116983", "entity_2_type_id": 114}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p12", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by [E1]perlecan[/E1], weak binding by decorin and [E2]biglycan[/E2], two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[85, 93]], "entity_1_idx_in_text_with_entity_marker": [89, 97], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "biglycan", "entity_2_idx": [[123, 131]], "entity_2_idx_in_text_with_entity_marker": [136, 144], "entity_2_type": "pm0124379", "entity_2_type_id": 115}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p18", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and [E1]biglycan[/E1], two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "biglycan", "entity_1_idx": [[123, 131]], "entity_1_idx_in_text_with_entity_marker": [127, 135], "entity_1_type": "pm0124379", "entity_1_type_id": 115, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p2", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag [E1]CD69[/E1], increases in cellular volume, RNA synthesis, and [E2]c-myc[/E2] protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD69", "entity_1_idx": [[226, 230]], "entity_1_idx_in_text_with_entity_marker": [230, 234], "entity_1_type": "pm0115739", "entity_1_type_id": 126, "entity_2": "c-myc", "entity_2_idx": [[281, 286]], "entity_2_idx_in_text_with_entity_marker": [294, 299], "entity_2_type": "pm0104123", "entity_2_type_id": 127}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s2_HPRD50.d36.s2.p2", "text": "The association of PTP-1C with CD22 was mediated by the NH2-terminal Src homology 2 (SH2) domain of PTP-1C", "text_with_entity_marker": "The association of PTP-1C with [E1]CD22[/E1] was mediated by the NH2-terminal Src homology 2 (SH2) domain of [E2]PTP-1C[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD22", "entity_1_idx": [[31, 35]], "entity_1_idx_in_text_with_entity_marker": [35, 39], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[100, 106]], "entity_2_idx_in_text_with_entity_marker": [113, 119], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s1_HPRD50.d38.s1.p1", "text": "Specific glutamines or lysines of involucrin were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain involucrin cross-links", "text_with_entity_marker": "Specific glutamines or lysines of [E1]involucrin[/E1] were used to cross-link the different proteins, such as glutamines 495 and 496 to desmoplakin, glutamine 288 to keratins, and lysines 468, 485, and 508 and glutamines 465 and 489 for interchain [E2]involucrin[/E2] cross-links", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "involucrin", "entity_1_idx": [[34, 44]], "entity_1_idx_in_text_with_entity_marker": [38, 48], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "involucrin", "entity_2_idx": [[239, 249]], "entity_2_idx_in_text_with_entity_marker": [252, 262], "entity_2_type": "pm0104308", "entity_2_type_id": 139}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p1", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated [E1]SRcyp[/E1]/CASP10, specifically interacts with the [E2]CTD[/E2] not only in vivo but also in vitro", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "SRcyp", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "CTD", "entity_2_idx": [[78, 81]], "entity_2_idx_in_text_with_entity_marker": [91, 94], "entity_2_type": "pm0113359", "entity_2_type_id": 146}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s0_HPRD50.d42.s0.p0", "text": "Herein, we show that a distinct IkappaB protein Bcl3 also interacts with RXR, as shown in the yeast two-hybrid tests and glutathione S-transferase pull-down assays", "text_with_entity_marker": "Herein, we show that a distinct IkappaB protein [E1]Bcl3[/E1] also interacts with RXR, as shown in the yeast two-hybrid tests and [E2]glutathione S-transferase[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Bcl3", "entity_1_idx": [[48, 52]], "entity_1_idx_in_text_with_entity_marker": [52, 56], "entity_1_type": "pm0126712", "entity_1_type_id": 151, "entity_2": "glutathione S-transferase", "entity_2_idx": [[121, 146]], "entity_2_idx_in_text_with_entity_marker": [134, 159], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p3", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "Bcl3 specifically interacted with the general transcription factors [E1]TFIIB[/E1], TBP, and [E2]TFIIA[/E2] but not with TFIIEalpha in the GST pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIB", "entity_1_idx": [[68, 73]], "entity_1_idx_in_text_with_entity_marker": [72, 77], "entity_1_type": "pm0112772", "entity_1_type_id": 153, "entity_2": "TFIIA", "entity_2_idx": [[84, 89]], "entity_2_idx_in_text_with_entity_marker": [97, 102], "entity_2_type": "pm0112153||pm0118250", "entity_2_type_id": 154}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s5_HPRD50.d42.s5.p0", "text": "In addition, coexpression of SRC-1 but not p300 further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR", "text_with_entity_marker": "In addition, coexpression of [E1]SRC-1[/E1] but not [E2]p300[/E2] further stimulated the Bcl3-mediated enhancement of the 9-cis-RA-induced transactivations of RXR", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRC-1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0108797||pm0117490", "entity_1_type_id": 155, "entity_2": "p300", "entity_2_idx": [[43, 47]], "entity_2_idx_in_text_with_entity_marker": [56, 60], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
